Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most route/dosing irritation/photosensitivity concepts are consistent with the label for FABIOR (tazarotene) Foam 0.1% used for acne vulgaris, but multiple claims are not supported by the provided label excerpts (notably plaque psoriasis, indication criteria wording, and several mechanistic/general retinoid effects phrased beyond the label).
Category Scores
Accurate Statements
Fabior is a prescription topical medicine.
The label excerpt describes FABIOR (tazarotene) Foam, and includes route-specific instructions for topical use only.
Tazarotene is a retinoid.
Section 12.1 Mechanism of Action describes tazarotene as a retinoid prodrug.
Topical tazarotene is typically applied once daily as directed to the affected area.
Section 2 Dosage and Administration: apply once daily in the evening...
Incorrect use of topical tazarotene can increase irritation.
Section 2: undue irritation—reduce frequency or interrupt; discontinue if persists. Section 10: excessive topical application may lead to marked redness, peeling, or discomfort.
Common side effects of topical retinoids include skin irritation, redness, burning, dryness, and peeling.
Section 5 and 2 describe skin redness, peeling, burning, discomfort; Section 6 provides local skin reactions (table not fully reproduced in excerpt).
Topical retinoids can increase sensitivity to sunlight.
Section 5.4: photosensitivity and risk for sunburn; heightened burning susceptibility; exposure to sunlight should be avoided.
Sun protection is often recommended with retinoid use.
Section 5.4: Patients must be warned to use sunscreens and protective clothing when using FABIOR Foam.
Unsupported Statements
Fabior most commonly refers to tazarotene.
No label excerpt provided addressing meanings of the brand name beyond identifying FABIOR as tazarotene foam.
Fabior is used as a trade name for tazarotene products.
Label excerpt identifies FABIOR (tazarotene) Foam, 0.1%; it does not explicitly state trade-name/general product usage beyond this product.
Tazarotene (Fabior) is used to treat plaque psoriasis in people who meet the product’s age/indication criteria.
Provided label excerpt (Section 1) indicates acne vulgaris only; no plaque psoriasis indication is shown.
Tazarotene (Fabior) is used to treat acne vulgaris depending on the formulation and local labeling.
The label excerpt provided specifies FABIOR Foam 0.1% is indicated for acne vulgaris in patients 12 years of age or older. The claim conditions on “depending on the formulation and local labeling” is not supported by the provided label excerpts.
Retinoids affect skin cell growth and differentiation.
Section 12.1 provides that the therapeutic effect may be due to anti-hyperproliferative and normalizing-of-differentiation effects, but the claim is generic and not directly quoted; not supported as stated.
Retinoids can help reduce abnormal scaling and inflammation seen in psoriasis and acne.
The label excerpt ties acne effect to anti-hyperproliferative/anti-inflammatory actions; it does not mention psoriasis or abnormal scaling in psoriasis.
Topical retinoids can increase sensitivity to sunlight.
While photosensitivity/sunburn risk is supported, the claim phrasing as a general class statement (“topical retinoids”) is broader than the label excerpt, which is specific to FABIOR Foam.
Sun protection is often recommended with retinoid use.
The label excerpt recommends sunscreens and protective clothing for FABIOR Foam; the claim uses generalized language not strictly confined to FABIOR.
Contradictions
High
AI Statement
Tazarotene (Fabior) is used to treat plaque psoriasis in people who meet the product’s age/indication criteria.
Label Reference
Section 1 INDICATIONS AND USAGE (provided): FABIOR Foam, 0.1% indicated for topical treatment of acne vulgaris in patients 12 years of age or older. No plaque psoriasis indication in provided excerpts.
Important Omissions
Age/indication criterion for acne vulgaris (12 years of age or older) is not included in the acne claim as written.
Importance:
Moderate
Pregnancy contraindication/fetal risk messaging is not addressed by the response claims.
Importance:
Moderate
Flammability warning for the foam propellant (avoid fire/flame/smoking during and immediately following application) is not mentioned.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
The biggest safety-relevant issue is the incorrect inclusion of plaque psoriasis as an indication, which is not supported by the provided FABIOR Foam label excerpts. Other statements are largely aligned with local irritation/photosensitivity concepts for FABIOR use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Plaque psoriasis indication is unsupported/contradicted by the provided FABIOR Foam label excerpt (which states acne vulgaris only). Several claims are generalized beyond the label (e.g., psoriasis mention, generic retinoid biology).
Suggested Improvement
Limit indications to the label-supported indication (acne vulgaris in patients ≥12 years for FABIOR Foam 0.1% as provided), avoid psoriasis claims, and restrict mechanistic/sun-sensitivity statements to what the label specifically supports for FABIOR Foam. Include key contraindication (pregnancy) and/or other major warnings if safety accuracy is needed.